Osteoporotic vertebral compression fractures (OVCFs) are common fractures in patients with osteoporosis. They can cause severe pain and limited mobility and may also lead to spinal deformity and an increased risk of subsequent fractures.
A recent retrospective, multi-center comparative cohort study evaluated the clinical outcomes of of a nutritional supplement containing vitamin K2 (MK-7), vitamin D3, and activated silicium, an oral food supplement containing bio-activated silicium and vitamins D3 and K2, as an adjunct to the conservative management of osteoporotic vertebral compression fractures.
1. Study Design
The study compared the six-month outcomes of patients with OVCFs who received standard conservative management alone with those who received standard conservative management supplemented with vitamin K2 (MK-7), vitamin D3, and activated silicium.
2. Supplementation group Showed Positive Results for Pain Reduction in OVCF Patients
2-1. Pain Reduction — Significant Improvement in NRS Scores
| ASSESSMENT | supplementation group | CONTROL GROUP |
|---|---|---|
| Baseline NRS | 8.26±0.99 | 8.26±0.93 |
| NRS at 6 months | 2.05 ± 2.17 | 3.84 ± 2.83 |
| Change from baseline | −6.21 ± 1.90 | −4.42 ± 2.12 |
At six months, the supplementation group showed a significantly lower NRS pain score than the control group. The reduction in NRS from baseline was also significantly greater in the supplementation group .
These results suggest that the supplement containing vitamin K2 (MK-7), vitamin D3, and activated silicium may provide additional benefits for pain reduction when used as an adjunct to conservative management of osteoporotic vertebral compression fractures.
2-2. Changes in Analgesic Use — Favorable Trend Toward Reduced Analgesic Burden
| Analgesic Use | supplementation group | Control Group |
|---|---|---|
| Complete discontinuation |
68.40% | 36.80% |
| Regular use | 10.50% | 21.10% |
The supplementation group showed a higher proportion of patients who discontinued analgesics and a lower proportion who continued regular analgesic use.
Although the difference was not statistically significant, the results indicated a favorable trend toward reduced analgesic use in the supplementation group.
3. How May Vitamin K2 (MK-7) Be Related to Pain and Bone Health?
Vitamin K2 (MK-7) is not a direct analgesic. Instead, it plays an important role in bone metabolism and mineralization.
4. New Potential of Vitamin K2 (MK-7) in Osteoporotic Vertebral Compression Fracture Recovery
The key finding of this study was that the addition of a nutritional supplement containing vitamin K2 (MK-7), vitamin D3, and activated silicium to standard conservative management was associated with a significantly greater reduction in pain after six months in patients with osteoporotic vertebral compression fractures.
The supplementation group also showed favorable trends in:
This study provides new clinical evidence suggesting the potential role of combined nutritional supplementation containing MK-7 in supporting bone health management in patients with osteoporotic vertebral compression fractures.
[Reference]
Gazzeri R, Galarza M, Occhigrossi F, Carulli C, Telera S, Mosca J, Leoni MLG. Oral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures. J Clin Med. 2026 Jul 3;15(13):5206. doi: 10.3390/jcm15135206.